Amit G. Singal, MD
Hepatocellular carcinoma (HCC), a disease that accounts for approximately 90% of liver cancers worldwide, is often diagnosed in the advanced stage where treatment options have been limited, according to Amit G. Singal, MD. However, recent data have led to first- and second-line changes in the landscape.
at the 2018 State of the Science Summit™ on Gastrointestinal Cancers, Singal, associate professor and medical director of the Liver Tumor Program and clinical chief of Hepatology at UT Southwestern Medical Center, discussed the evolving armamentarium of treatment options for patients with HCC.
OncLive: What were the key points from your presentation?
: HCC is a cancer that is actually increasing in incidence and mortality in the United States. While we are making great progress in other cancers, the relevance and unmet need of HCC is rapidly increasing. Over the last decade, the HCC incidence has more than doubled, according to some data we have. One of the things we talked about is some of the interesting and exciting progress made in terms of treatment, particularly in advanced HCC management. This is important because most HCC cases occur in the advanced stage when they aren't eligible for curative therapies.
... to read the full story